Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

The Effects of Escitalopram on Cytokines

Not Applicable
Conditions
Interventions
First Posted Date
2012-04-30
Last Posted Date
2012-05-15
Lead Sponsor
Beitou Armed Forces Hospital, Taipei, Taiwan
Target Recruit Count
25
Registration Number
NCT01587326
Locations
🇨🇳

Beitou Armed Forces Hospital, Taipei, Taiwan

Escitalopram Treatment In Acute Stroke

Phase 4
Withdrawn
Conditions
Interventions
First Posted Date
2012-03-22
Last Posted Date
2012-06-19
Lead Sponsor
University of Aarhus
Registration Number
NCT01561092
Locations
🇩🇰

Neurology Department, University Hospital of Aarhus, Aarhus, Denmark

🇩🇰

Neurology Department, Glostrup Hospital, Glostrup, Denmark

🇩🇰

Neurology Department, Aalborg Hospital, Aalborg, Denmark

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-03-12
Last Posted Date
2017-01-12
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
32
Registration Number
NCT01551225
Locations
🇳🇱

Maastricht University Medical Center, Maastricht, Netherlands

Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

First Posted Date
2012-03-01
Last Posted Date
2014-04-10
Lead Sponsor
Ewha Womans University
Target Recruit Count
60
Registration Number
NCT01541475
Locations
🇰🇷

Seoul National University Hospital, Biomedical Research Institute, Seoul, Korea, Republic of

Escitalopram in the Treatment of Postpartum Depression

Not Applicable
Completed
Conditions
First Posted Date
2012-02-07
Last Posted Date
2012-02-10
Lead Sponsor
BC Women's Hospital & Health Centre
Target Recruit Count
20
Registration Number
NCT01527474
Locations
🇨🇦

Reproductive Mental Health Program, BC Women's Hospital, Vancouver, British Columbia, Canada

Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2012-01-31
Last Posted Date
2017-03-29
Lead Sponsor
Hull University Teaching Hospitals NHS Trust
Registration Number
NCT01522092
Locations
🇬🇧

Respiratory Medicine, Clinical trials Unit, Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

First Posted Date
2011-12-01
Last Posted Date
2013-12-18
Lead Sponsor
Baker Heart and Diabetes Institute
Target Recruit Count
40
Registration Number
NCT01483053
Locations
🇦🇺

Monash Medical Centre - Monash Health, Clayton, Victoria, Australia

🇦🇺

Alfred and Baker Medical Unit - Alfred Hospital, Melbourne, Victoria, Australia

🇦🇺

Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

First Posted Date
2011-11-24
Last Posted Date
2024-04-29
Lead Sponsor
Loyola University
Target Recruit Count
100
Registration Number
NCT01479829
Locations
🇺🇸

Loyola University Medical Center, Maywood, Illinois, United States

Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders

First Posted Date
2011-11-22
Last Posted Date
2016-09-14
Lead Sponsor
Medical University of Vienna
Target Recruit Count
289
Registration Number
NCT01477203
Locations
🇦🇹

Medical University of Vienna, Department for Psychiatrie and Psychotherapie, Vienna, Austria

Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-09-08
Last Posted Date
2013-06-05
Lead Sponsor
Hvidovre University Hospital
Target Recruit Count
120
Registration Number
NCT01430520
Locations
🇩🇰

Vejle Sygehus, Vejle, Denmark

🇩🇰

Gentofte Hospital, Gentofte, Hellerup, Denmark

🇩🇰

Regionshospitalet Holstebro, Holstebro, Denmark

© Copyright 2024. All Rights Reserved by MedPath